Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 9, 2004, Pages 951-957

  Tobias, J H ^a   Sasi, M R ^a   Greenwood, R ^a   Probert, C S J ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CALCIUM INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; FEMALE; FEMUR NECK; HIP; HUMAN; LUMBAR SPINE; MALE; OSTEOLYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGE OF ONSET; BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; CROHN DISEASE; FEMALE; FEMUR NECK; GLUCOCORTICOIDS; HUMANS; LUMBAR VERTEBRAE; MALE; PREDNISOLONE;

EID: 9944254205     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02207.x     Document Type: Article

References (28)

1. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-9.
2. van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003; 125: 1591-7.
3. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 1031-9.
4. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313-9.
5. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6.
6. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner 2000; 15: 993-1000.
7. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 1999; 34: 696-702.
8. Stockbrugger RW, Schoon EJ, Bollani S, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1519-27.
9. Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002; 8: 87-92.
10. Bjarnason I, Macpherson A. Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228-33.
11. de Jong DJ, Corstens FH, Mannaerts L, van Rossum LG, Naber AH. Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? Am J Gastroenterol 2002; 97: 2011-5.
12. de Jong DJ, Mannaerts L, van Rossum LG, Corstens FH, Naber AH. Longitudinal study of bone mineral density in patients with Crohn's disease. Dig Dis Sci 2003; 48: 1355-9.
13. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, Van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993; 119: 963-8.
14. Prentice A. What are the dietary requirements for calcium and vitamin D? Calcif Tiss Int 2002; 70: 83-8.
15. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1121-7.
16. von Tirpitz C, Klaus J, Steinkamp M, et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003; 17: 807-16.
17. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5: 156-60.
18. Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women with systemic lupus erythromatosus. Clin Rheumatol 2003; 22: 318-23.
19. Petri M. Osteoporosis in SLE: prednisolone affects lumbar spine more than other areas. Arthritis Rheum 1996; 39: S667.
20. Motley RJ, Crawley EO, Evans C. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988; 29: 1332-6.
21. Pollack RD, Karmeli F, Eliakim R, Ackerman Z, Tubb K, Rachmileowitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 1483-90 (abstract).
22. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1895.
23. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410-5.
24. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004; 53: 251-5.
25. Loftus EV, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon V, Melton LJ. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnestota. Gastroenterology 2002; 123: 468-75.
26. Silvennoinen J, Lamberg-Allardt C, Karkkainen M, Niemela S, Lehtola J. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med 1996; 240: 285-92.
27. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999; 42: 2309-18.
28. Lin CL, Moniz C, Chow JW. Treatment with fluoride or bisphosphonates prevents bone loss associated with colitis in the rat. Calcif Tissue Int 2000; 67: 373-7.